Ann S. LaCasce, MD, MMSc, on Relapsed/Refractory Indolent Follicular Lymphoma: Management Updates
NCCN 2022 Annual Conference
Ann S. LaCasce, MD, MMSc, of Dana-Farber Cancer Institute, discusses the various agents available to treat patients with indolent B-cell lymphomas: lenalidomide plus rituximab, which has a superior progression-free survival profile compared with rituximab monotherapy; the PI3K inhibitors copanlisib and umbralisib, which have similar efficacy yet distinct side-effect profiles; tazemetostat, which is active in both EZH2-mutant and Warthin’s tumor disease; and CAR T-cell therapy, which shows early activity.
The ASCO Post Staff
Reid M. Ness, MD, MPH, of Vanderbilt-Ingram Cancer Center, discusses significant updates to the NCCN Clinical Practice Guidelines in Oncology for colorectal cancer screening: lowering the age from 50 to 45 for the initiation of average-risk screening for all combinations of race, ethnicity, and sex; and extending the surveillance interval from 5 to 7–10 years following the identification of one to two low-risk adenomas.
The ASCO Post Staff
Margaret A. Tempero, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the most effective ways to use the regimens available to treat patients with pancreatic cancer (FOLFIRINOX [fluorouracil, leucovorin, irinotecan, and oxaliplatin] and gemcitabine plus albumin-bound paclitaxel). Dr. Tempero also reviews the upfront use of chemotherapy for resectable disease, and ways to modify these therapies to make them more tolerable for patients. Looking ahead, she expresses hope for the new drugs under development, which may inactivate RAS, a major driver of the disease.
The ASCO Post Staff
Genevieve Boland, MD, PhD, of Massachusetts General Hospital Cancer Center, discusses targeted treatments and immunotherapies and how they have dramatically changed the landscape in melanoma. Initially used in advanced disease, these agents are now being used in local or locoregional melanoma in the adjuvant and/or neoadjuvant settings. Dr. Boland also talks about the critical importance of multidisciplinary teams to integrate the latest recommendations for patient care.
The ASCO Post Staff
Smitha S. Krishnamurthi, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses prognostic assays for localized colon cancer, the potential clinical uses and current limitations of prognostic assays for stage II to III disease, and checkpoint inhibitor therapy for metastatic colorectal cancer.
The ASCO Post Staff
Thomas W. Flaig, MD, of the University of Colorado Cancer Center, discusses the rapidly changing treatment landscape for patients with bladder cancer, including PD-1 and PD-L1 inhibitors now approved for urothelial carcinoma; a category 1 indication for pembrolizumab in metastatic disease, post-platinum treatment and for non–muscle-invasive bladder cancer; enfortumab vedotin-ejfv for subsequent-line use; and erdafitinib for those with select FGFR mutations.
